243 related articles for article (PubMed ID: 35126846)
1. Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence.
Jeyakumar SM; Vajreswari A
World J Hepatol; 2022 Jan; 14(1):168-179. PubMed ID: 35126846
[TBL] [Abstract][Full Text] [Related]
2. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.
Aljohani A; Khan MI; Bonneville A; Guo C; Jeffery J; O'Neill L; Syed DN; Lewis SA; Burhans M; Mukhtar H; Ntambi JM
J Biol Chem; 2019 Dec; 294(51):19475-19485. PubMed ID: 31690632
[TBL] [Abstract][Full Text] [Related]
3. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase.
Li ZZ; Berk M; McIntyre TM; Feldstein AE
J Biol Chem; 2009 Feb; 284(9):5637-44. PubMed ID: 19119140
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content.
Siddiqui RA; Xu Z; Harvey KA; Pavlina TM; Becker MJ; Zaloga GP
Nutr Metab (Lond); 2015; 12():41. PubMed ID: 26583036
[TBL] [Abstract][Full Text] [Related]
5. SCD1 deficiency protects mice against ethanol-induced liver injury.
Lounis MA; Escoula Q; Veillette C; Bergeron KF; Ntambi JM; Mounier C
Biochim Biophys Acta; 2016 Nov; 1861(11):1662-1670. PubMed ID: 27477676
[TBL] [Abstract][Full Text] [Related]
6. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
Elife; 2023 Aug; 12():. PubMed ID: 37580962
[TBL] [Abstract][Full Text] [Related]
8. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
[TBL] [Abstract][Full Text] [Related]
9. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios.
Peter A; Cegan A; Wagner S; Lehmann R; Stefan N; Königsrainer A; Königsrainer I; Häring HU; Schleicher E
Clin Chem; 2009 Dec; 55(12):2113-20. PubMed ID: 19850634
[TBL] [Abstract][Full Text] [Related]
10. Dietary polyunsaturated fatty acids mediate the inverse association of stearoyl-CoA desaturase activity with the risk of fatty liver in dyslipidaemic individuals.
Amor AJ; Cofán M; Mateo-Gallego R; Cenarro A; Civeira F; Ortega E; Ros E; Sala-Vila A
Eur J Nutr; 2019 Jun; 58(4):1561-1568. PubMed ID: 29675558
[TBL] [Abstract][Full Text] [Related]
11. Carrot Juice Administration Decreases Liver Stearoyl-CoA Desaturase 1 and Improves Docosahexaenoic Acid Levels, but Not Steatosis in High Fructose Diet-Fed Weanling Wistar Rats.
Mahesh M; Bharathi M; Reddy MR; Kumar MS; Putcha UK; Vajreswari A; Jeyakumar SM
Prev Nutr Food Sci; 2016 Sep; 21(3):171-180. PubMed ID: 27752492
[TBL] [Abstract][Full Text] [Related]
12. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.
Jiang G; Li Z; Liu F; Ellsworth K; Dallas-Yang Q; Wu M; Ronan J; Esau C; Murphy C; Szalkowski D; Bergeron R; Doebber T; Zhang BB
J Clin Invest; 2005 Apr; 115(4):1030-8. PubMed ID: 15761499
[TBL] [Abstract][Full Text] [Related]
13. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
14. Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial.
Costabile G; Della Pepa G; Salamone D; Luongo D; Naviglio D; Brancato V; Cavaliere C; Salvatore M; Cipriano P; Vitale M; Corrado A; Rivellese AA; Annuzzi G; Bozzetto L
Nutrients; 2022 May; 14(10):. PubMed ID: 35631319
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
Zhang M; Tang Y; Tang E; Lu W
Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
[TBL] [Abstract][Full Text] [Related]
16. Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma.
Ducheix S; Piccinin E; Peres C; Garcia-Irigoyen O; Bertrand-Michel J; Fouache A; Cariello M; Lobaccaro JM; Guillou H; Sabbà C; Ntambi JM; Moschetta A
Hepatol Commun; 2022 Oct; 6(10):2937-2949. PubMed ID: 35903850
[TBL] [Abstract][Full Text] [Related]
17. Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis.
Hua MC; Su HM; Yao TC; Kuo ML; Lai MW; Tsai MH; Huang JL
PLoS One; 2017; 12(7):e0182277. PubMed ID: 28759573
[TBL] [Abstract][Full Text] [Related]
18. Hepatic oleate regulates liver stress response partially through PGC-1α during high-carbohydrate feeding.
Liu X; Burhans MS; Flowers MT; Ntambi JM
J Hepatol; 2016 Jul; 65(1):103-112. PubMed ID: 26976120
[TBL] [Abstract][Full Text] [Related]
19. SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors.
Sun Q; Xing X; Wang H; Wan K; Fan R; Liu C; Wang Y; Wu W; Wang Y; Wang R
Biomed Pharmacother; 2024 Jan; 170():115586. PubMed ID: 38042113
[TBL] [Abstract][Full Text] [Related]
20. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet.
Silbernagel G; Kovarova M; Cegan A; Machann J; Schick F; Lehmann R; Häring HU; Stefan N; Schleicher E; Fritsche A; Peter A
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2288-92. PubMed ID: 23015656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
